Therapeutics against influenza

Elena A. Govorkova, Jonathan Mccullers

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Citations (Scopus)

Abstract

Despite 75 years of research into prevention and treatment of influenza, the viruses that cause this disease continue to rank as some of the most important pathogens afflicting humans today. Progress in development of therapeutics for influenza has been slow for much of that time, but has accelerated in pace over the last two decades. Two classes of antiviral medications are used in humans at present, but each has limitations in scope and effectiveness of use. New strategies involving these licensed agents, including alternate forms of delivery and combination therapy with other drugs, are currently being explored. In addition, several novel antiviral compounds are in various clinical phases of development. Together with strategies designed to target the virus itself, new approaches to interrupt host-pathogen interactions or modulate detrimental aspects of the immune response have been proposed. Therapy for influenza will likely undergo substantial changes in the decades to come, evolving with our knowledge of pathogenesis as new approaches become viable and are validated clinically.

Original languageEnglish (US)
Title of host publicationSwine Influenza
Pages273-300
Number of pages28
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Publication series

NameCurrent Topics in Microbiology and Immunology
Volume370
ISSN (Print)0070-217X

Fingerprint

Human Influenza
Antiviral Agents
Host-Pathogen Interactions
Virus Diseases
Orthomyxoviridae
Therapeutics
Viruses
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Microbiology
  • Immunology
  • Microbiology (medical)

Cite this

Govorkova, E. A., & Mccullers, J. (2013). Therapeutics against influenza. In Swine Influenza (pp. 273-300). (Current Topics in Microbiology and Immunology; Vol. 370). https://doi.org/10.1007/82-2011-198

Therapeutics against influenza. / Govorkova, Elena A.; Mccullers, Jonathan.

Swine Influenza. 2013. p. 273-300 (Current Topics in Microbiology and Immunology; Vol. 370).

Research output: Chapter in Book/Report/Conference proceedingChapter

Govorkova, EA & Mccullers, J 2013, Therapeutics against influenza. in Swine Influenza. Current Topics in Microbiology and Immunology, vol. 370, pp. 273-300. https://doi.org/10.1007/82-2011-198
Govorkova EA, Mccullers J. Therapeutics against influenza. In Swine Influenza. 2013. p. 273-300. (Current Topics in Microbiology and Immunology). https://doi.org/10.1007/82-2011-198
Govorkova, Elena A. ; Mccullers, Jonathan. / Therapeutics against influenza. Swine Influenza. 2013. pp. 273-300 (Current Topics in Microbiology and Immunology).
@inbook{7fb1e2c7e504413b88b54683ac371a65,
title = "Therapeutics against influenza",
abstract = "Despite 75 years of research into prevention and treatment of influenza, the viruses that cause this disease continue to rank as some of the most important pathogens afflicting humans today. Progress in development of therapeutics for influenza has been slow for much of that time, but has accelerated in pace over the last two decades. Two classes of antiviral medications are used in humans at present, but each has limitations in scope and effectiveness of use. New strategies involving these licensed agents, including alternate forms of delivery and combination therapy with other drugs, are currently being explored. In addition, several novel antiviral compounds are in various clinical phases of development. Together with strategies designed to target the virus itself, new approaches to interrupt host-pathogen interactions or modulate detrimental aspects of the immune response have been proposed. Therapy for influenza will likely undergo substantial changes in the decades to come, evolving with our knowledge of pathogenesis as new approaches become viable and are validated clinically.",
author = "Govorkova, {Elena A.} and Jonathan Mccullers",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/82-2011-198",
language = "English (US)",
isbn = "9783642368707",
series = "Current Topics in Microbiology and Immunology",
pages = "273--300",
booktitle = "Swine Influenza",

}

TY - CHAP

T1 - Therapeutics against influenza

AU - Govorkova, Elena A.

AU - Mccullers, Jonathan

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Despite 75 years of research into prevention and treatment of influenza, the viruses that cause this disease continue to rank as some of the most important pathogens afflicting humans today. Progress in development of therapeutics for influenza has been slow for much of that time, but has accelerated in pace over the last two decades. Two classes of antiviral medications are used in humans at present, but each has limitations in scope and effectiveness of use. New strategies involving these licensed agents, including alternate forms of delivery and combination therapy with other drugs, are currently being explored. In addition, several novel antiviral compounds are in various clinical phases of development. Together with strategies designed to target the virus itself, new approaches to interrupt host-pathogen interactions or modulate detrimental aspects of the immune response have been proposed. Therapy for influenza will likely undergo substantial changes in the decades to come, evolving with our knowledge of pathogenesis as new approaches become viable and are validated clinically.

AB - Despite 75 years of research into prevention and treatment of influenza, the viruses that cause this disease continue to rank as some of the most important pathogens afflicting humans today. Progress in development of therapeutics for influenza has been slow for much of that time, but has accelerated in pace over the last two decades. Two classes of antiviral medications are used in humans at present, but each has limitations in scope and effectiveness of use. New strategies involving these licensed agents, including alternate forms of delivery and combination therapy with other drugs, are currently being explored. In addition, several novel antiviral compounds are in various clinical phases of development. Together with strategies designed to target the virus itself, new approaches to interrupt host-pathogen interactions or modulate detrimental aspects of the immune response have been proposed. Therapy for influenza will likely undergo substantial changes in the decades to come, evolving with our knowledge of pathogenesis as new approaches become viable and are validated clinically.

UR - http://www.scopus.com/inward/record.url?scp=84893104316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893104316&partnerID=8YFLogxK

U2 - 10.1007/82-2011-198

DO - 10.1007/82-2011-198

M3 - Chapter

SN - 9783642368707

T3 - Current Topics in Microbiology and Immunology

SP - 273

EP - 300

BT - Swine Influenza

ER -